Cargando…

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer

Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control. Very few studies have investigated salvage chemotherapy after failure of GEM or GEM-containing chemotherapy and preclinical studies attempting to widen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercalli, A, Sordi, V, Formicola, R, Dandrea, M, Beghelli, S, Scarpa, A, Di Carlo, V, Reni, M, Piemonti, L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360188/ https://www.ncbi.nlm.nih.gov/pubmed/17426706 http://dx.doi.org/10.1038/sj.bjc.6603726

Ejemplares similares

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
por: Vilar, E, et al.
Publicado: (2008)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
por: Xu, Li, et al.
Publicado: (2017)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer
por: Wei, J, et al.
Publicado: (2014)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy
por: Karagounis, Ilias V, et al.
Publicado: (2016)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
por: Pothula, Srinivasa P, et al.
Publicado: (2016)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma
por: Karakhanova, S, et al.
Publicado: (2015)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
por: Rosa, R, et al.
Publicado: (2013)

Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice
por: Forest, V, et al.
Publicado: (2009)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)

The x(c)(−) cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
por: Lo, M, et al.
Publicado: (2008)

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011)

Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain
por: Kalra, A V, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_7n2gvd315f4pke50bs9ebogb1l